Last weekend, President Donald Trump signed an executive order aimed at accelerating the review of psychedelic therapies for mental health conditions. At a high level, the order does three things. It ...
Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...
COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising ...
The White House is in for a trip.
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...
Compass Pathways (CMPS) added ~20% in the premarket on Tuesday after the U.K.-based biotech announced that its psychedelic therapy COMP360 reached the primary endpoint in a late-stage trial for ...
The Daily Caller on MSN
How Trump admin’s psychedelic drug research push could shake up US mental healthcare system
The Trump administration’s recent push for psychedelic drugs in mental healthcare may significantly shake up the industry.
At a high level, the order does three things. It shortens the timeline for clinical trials and regulatory review, it helps normalize these therapies in the eyes of both patients and providers, and it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results